How representative are clinical trial cohorts of the general CF population? Implications for trial planning

It is a common phenomenon that trial participants are not fully representative of the clinical population [1], and this is so in cystic fibrosis (CF) trials [2]. This may lead to uncertainties about the safety and efficacy of drugs when they are prescribed to the more heterogeneous clinical population. Additionally, restrictive eligibility criteria reduce the number of patients available to take part in research. The CF trials space is congested and understanding the number of patients eligible to participate in research is important to design protocols and define research priorities at local, national and international levels.
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Short Communication Source Type: research